FOXO4-DRI vs Vesilute
Comprehensive side-by-side comparison of mechanisms, dosing, side effects, and research
Also: FOX04-DRI, FOXO4 D-Retro-Inverso
A senolytic peptide designed to selectively eliminate senescent 'zombie' cells by disrupting the FOXO4-p53 interaction. Shows promise for restoring tissue function in aging, including kidney health restoration.
Also: ED Dipeptide, Glu-Asp
A synthetic dipeptide (Glu-Asp) bioregulator from the Khavinson peptide family, studied for urinary tract and prostate support. Research suggests it may help with bladder function and prostate microcirculation. Part of the tissue-specific bioregulatory compounds developed over 40+ years of research.
Key Comparison Insights
- Both peptides belong to the Anti-Aging category, suggesting similar primary applications.
- FOXO4-DRI has stronger research evidence (Animal Studies) compared to Vesilute (Preclinical).
Detailed Comparison
| Attribute | FOXO4-DRI | Vesilute |
|---|---|---|
| Category | Anti-Aging | Anti-Aging |
| FDA Status | Not FDA Approved | Not FDA Approved |
| Clinical Status | Pre I II III IV FDA | Pre I II III IV FDA |
| Mechanism of Action | FOXO4-DRI is a D-retro-inverso peptide that interferes with the binding between FOXO4 and p53 proteins. In senescent cells, FOXO4 binds to p53 to prevent apoptosis, allowing these dysfunctional cells to persist. FOXO4-DRI competes for this binding, releasing p53 to trigger apoptosis specifically in senescent cells while sparing healthy cells. | Vesilute is a dipeptide bioregulator that targets urogenital tissue. It is believed to normalize cellular function by reducing peptide deficiency and restoring protein synthesis inside cells. Research suggests it may enhance microcirculation within the prostate and support bladder function through epigenetic regulation of gene expression. |
| Common Dosing | 2-10 mg every other day for 3 doses (one cycle) 3 doses every other day, 1-3 cycles per year | 1-2 capsules (10-20 mg) daily 1-2x daily, before meals |
| Administration | Subcutaneous injection (community), IV/IP in animal studies | Oral capsules |
| Typical Duration | 1 cycle = 3 doses over 5-6 days, repeat 1-3x yearly | 30-day courses, repeat after 4-6 months |
| Best Time to Take | Per research protocol | Morning, before meals |
Possible Side Effects May vary by individual |
|
|
| Research Summary | Landmark 2017 Cell study demonstrated that FOXO4-DRI restored fitness, fur density, and renal function in aged mice. Studies show improved kidney tubular cell markers, better urea/creatinine metrics, and reduced SASP (senescence-associated secretory phenotype) cytokines. A 2025 Nature Communications study provided detailed structural insights into the FOXO4-p53 interaction mechanism. Cleara Biotech is developing FOXO4-DRI for conditions including kidney disease, COPD, and osteoarthritis. | Part of Professor Khavinson's bioregulator research at the Saint Petersburg Institute of Bioregulation and Gerontology. Studies investigate potential role in supporting urinary tract and prostate health. Research suggests it may alleviate symptoms linked to bladder dysfunction and reduce prostate issues by improving local circulation. Limited published peer-reviewed data compared to other Khavinson peptides. |
Frequently Asked Questions: FOXO4-DRI vs Vesilute
What is the difference between FOXO4-DRI and Vesilute?
FOXO4-DRI is a anti-aging peptide that a senolytic peptide designed to selectively eliminate senescent 'zombie' cells by disrupting the foxo4-p53 interaction. shows promise for restoring tissue function in aging, including kidney health restoration. Vesilute is a anti-aging peptide that a synthetic dipeptide (glu-asp) bioregulator from the khavinson peptide family, studied for urinary tract and prostate support. research suggests it may help with bladder function and prostate microcirculation. part of the tissue-specific bioregulatory compounds developed over 40+ years of research. The main differences lie in their mechanisms of action and clinical applications.
Which is better, FOXO4-DRI or Vesilute?
Neither is universally "better" - the choice depends on your specific goals. FOXO4-DRI is typically used for anti-aging purposes, while Vesilute is used for anti-aging. Always consult with a healthcare provider to determine which may be appropriate for your situation.
Can FOXO4-DRI and Vesilute be used together?
Some peptide protocols combine multiple compounds for synergistic effects. However, using FOXO4-DRI and Vesilute together should only be considered under medical supervision, as both compounds have their own side effect profiles and potential interactions. Research on their combined use may be limited.
Related Comparisons
View Full Peptide Profiles
Educational Information Only
This comparison of FOXO4-DRI and Vesilute is for educational purposes only. Neither this comparison nor any information on this site constitutes medical advice. Always consult with qualified healthcare providers before making decisions about peptides or other substances.